BOWIE, Md. – June 2, 2014 – Inovalon, Inc., a leading technology company providing advanced cloud-based analytics and data-driven solutions to the healthcare industry, today announced medication quality measure performance and pharmacovigilance research studies to be presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting May 31-June 4 in Montreal, Quebec.
Inovalon’s Statistical Research Team will present the following studies:
Disparity in High Risk Medication Use between Dual and Non-Dual Eligible Medicare Advantage Beneficiaries: A Decomposition Analysis. The goal of this research was to identify those factors contributing to consistently worse performance on clinical outcome measures among Dual Eligible (DE) Medicare Advantage beneficiaries—those eligible for both Medicare and Medicaid—to help guide interventions and policies aimed at improving care for this vulnerable population. Specific objectives were to evaluate the disparity in high risk medication (HRM) use between DE and traditional Medicare Advantage members (non-DE), and to examine the contributions of DE member characteristics to the observed disparity. The study found that HRM use is 27% higher in DE beneficiaries. According to the study’s authors, differences in DE member characteristics can explain only about half the performance gap, and that differential is mainly attributable to the greater severity of illness burden among DEs as measured by the Charlson comorbidity score.
Association between Asthma-Related Healthcare Utilization and Two Different Types of Asthma Treatments among a Commercially Insured Adolescent and Adult Population. The objective was to evaluate the relationship between risk of asthma-related healthcare utilization with two different types of asthma therapies—inhaled corticosteroids (ICS) alone and fixed-dose combination of long-acting beta-agonists (LABA) and ICS—among a commercially insured adolescent and adult population. The study found the risk of asthma-related healthcare utilization is statistically significantly higher in users of fixed-dose LABA and ICS combination therapy than in users of ICS alone. According to the authors, this large retrospective analysis adds further evidence to the ongoing debate over whether the high use and added cost of fixed-dose LABA and ICS combination therapy is consistent with the triple aim of providing better care, better health, and better value to the healthcare system.
“Inovalon is harnessing the power of large longitudinal data using sophisticated analytics to better understand differential performance on quality outcomes at the member level,” said Dan Rizzo, Chief Innovation Officer at Inovalon. “These comparative effectiveness research studies will provide new data-driven evidence regarding what works best under what conditions for which patients.”
The studies were supported by data from Inovalon’s Medical Outcomes Research for Effectiveness and Economics (MORE2 Registry®). Inovalon’s Statistical Research Team co-authors include: Zulkarnain Pulungan, PhD; Alexis Parente, PhD; Sandhya Mehta, PhD; Barton T. Jones, MS; Christie Teigland, PhD.
The presentations will be held on Monday, June 2, 2014 at 3:45 p.m. and Tuesday, June, 2014 at 8:30 am.
About Inovalon, Inc
Inovalon is a leading technology company that combines advanced cloud-based data analytics with highly targeted interventions to achieve meaningful impact in clinical and quality outcomes, utilization, and financial performance across the healthcare landscape. Inovalon’s unique achievement of value is delivered through the effective progression of Turning Data into Insight, and Insight into Action®. Large proprietary datasets, advanced integration technologies, sophisticated predictive analytics, and deep subject matter expertise deliver a seamless, end-to-end platform of technology and nationwide operations that bring the benefits of big data and large-scale analytics to the point of care. Driven by data, Inovalon uniquely identifies gaps in care, quality, data integrity, and financial performance – while also bringing to bear the unique capabilities to resolve them. Touching more than 540,000 physicians, 220,000 clinical facilities, and more than 140 million Americans, this differentiating combination provides a powerful solution suite that drives high-value impact, improving quality and economics for health plans, ACOs, hospitals, physicians, patients, and researchers. For more information visit www.inovalon.com
Kim E. Collins
4321 Collington Road
Bowie, Maryland 20716
Phone: 301-809-4000 x1473